Showing results (961-970 of 1,124) with videos related to
Sort By:
Pageof 113
Journal of Clinical and Translational Science|August 13, 2019
Come from away: Best practices in mini-sabbaticals for the development of young investigators: a White Paper by the SEQUIN (mini-Sabbatical Evaluation and QUality ImprovemeNt) GroupMichael H Pillinger, Stephenie C Lemon, Martin S Zand, et al.JCI Insight|January 21, 2021
A GRM7 mutation associated with developmental delay reduces mGlu7 expression and produces neurological phenotypesNicole M Fisher, Aqeela AlHashim, Aditi B Buch, et al.Journal of Medicinal Chemistry|August 23, 2014
Development of a highly potent, novel M5 positive allosteric modulator (PAM) demonstrating CNS exposure: 1-((1H-indazol-5-yl)sulfoneyl)-N-ethyl-N-(2-(trifluoromethyl)benzyl)piperidine-4-carboxamide (ML380)Patrick R Gentry, Masaya Kokubo, Thomas M Bridges, et al.Bioorganic & Medicinal Chemistry Letters|July 4, 2012
Development of novel M1 antagonist scaffolds through the continued optimization of the MLPCN probe ML012Bruce J Melancon, Thomas J Utley, Christian Sevel, et al.Bioorganic & Medicinal Chemistry Letters|December 4, 2012
Further exploration of M₁ allosteric agonists: subtle structural changes abolish M₁ allosteric agonism and result in pan-mAChR orthosteric antagonismDouglas J Sheffler, Christian Sevel, Uyen Le, et al.Neuron|December 22, 2017
Cholinergic Projections to the Substantia Nigra Pars Reticulata Inhibit Dopamine Modulation of Basal Ganglia through the M4 Muscarinic ReceptorMark S Moehle, Tristano Pancani, Nellie Byun, et al.Bioorganic & Medicinal Chemistry Letters|January 4, 2011
Discovery and optimization of a novel, selective and brain penetrant M1 positive allosteric modulator (PAM): the development of ML169, an MLPCN probePaul R Reid, Thomas M Bridges, Douglas J Sheffler, et al.Journal of Medicinal Chemistry|January 21, 2011
Discovery, synthesis, and structure-activity relationship development of a series of N-(4-acetamido)phenylpicolinamides as positive allosteric modulators of metabotropic glutamate receptor 4 (mGlu(4)) with CNS exposure in ratsDarren W Engers, Julie R Field, Uyen Le, et al.The Journal of Pharmacology and Experimental Therapeutics|January 30, 2004
A novel selective allosteric modulator potentiates the activity of native metabotropic glutamate receptor subtype 5 in rat forebrainJulie A O'Brien, Wei Lemaire, Marion Wittmann, et al.The Journal of Pharmacology and Experimental Therapeutics|September 6, 2008
Centrally active allosteric potentiators of the M4 muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotor activity in ratsAshley E Brady, Carrie K Jones, Thomas M Bridges, et al.Pageof 113